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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 72, Revision 1 
(FGE.72Rev1): Consideration of aliphatic, branched-chain saturated and 
unsaturated alcohols, aldehydes, acids, and related esters evaluated by the 
JECFA (61
st
 meeting) structurally related to branched- and straight-chain 
unsaturated carboxylic acids, esters of these and straight-chain aliphatic 
saturated alcohols evaluated by EFSA in FGE.05Rev2
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific opinion, published on 5 December 2013, replaces the earlier version published on 16 
October 2013*. 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of 23 aliphatic branched-chain saturated and unsaturated alcohols, aldehydes, acids and related esters, 
evaluated by the JECFA at their 61
st
 meeting. This revision is made due to inclusion of one additional substance, 
2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] cleared for genotoxicity concern in FGE.207. The 
substances were evaluated through a stepwise approach that integrates information on structure-activity 
relationships, intake from current uses, toxicological threshold of concern, and available data on metabolism and 
toxicity. The Panel agrees with the application of the Procedure as performed by the JECFA for all 23 substances 
considered in this FGE and agrees with the JECFA conclusion, “No safety concern at estimated levels of intake 
as flavouring substances” based on the MSDI approach. Besides the safety assessment of these flavouring 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2013-00551, adopted on 25 September 2013. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, 
Alessandro Di Domenico, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter 
Jany, Martine Kolf-Clauw, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de Fatima Tavares 
Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine 
Husøy, Wim Mennes, Gerard Mulder and Harriet Wallin for the preparatory work on this scientific opinion and the hearing 
experts: Vibe Beltoft, Pia Lund and Karin Nørby and EFSA staff: AnnaMaria Rossi and Kim Rygaard Nielsen for the 
support provided to this scientific opinion. 
*  Minor changes of editorial nature were made. The changes do not affect the contents of this report. To avoid confusion, the 
original version of the opinion has been removed from the website, but is available on request, as is a version showing all 
the changes made. 
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substances, the specifications for the materials of commerce have also been considered and for all 23 substances, 
the information is adequate. 
© European Food Safety Authority, 2013 
 
KEY WORDS 
flavouring safety, JECFA, aliphatic branched-chain, alcohols, aldehydes, acids, FGE.05Rev2 
Flavouring Group Evaluation 72, Revision 1 
 
EFSA Journal 2013;11(10):3392 3 
SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific advice to the 
Commission on the implications for human health of chemically defined flavouring substances used in 
or on foodstuffs in the Member States. In particular, the CEF Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
In the first version of Flavouring Group Evaluation 72 (FGE.72), EFSA considered a group of 22 
aliphatic branched-chain saturated and unsaturated alcohols, aldehydes, acids and related esters which 
had been evaluated by the JECFA at their 61
st
 meeting.  
The present revision of FGE.72 is prepared due to inclusion of one additional substance, 2,6-dimethyl-
2,5,7-octatriene-1-ol acetate [FL-no: 09.931], which has been cleared for genotoxicity concern in 
FGE.207. Furthermore, European tonnage data for two substances [FL-no: 05.148 and 08.079] as well 
as information on the stereoisomeric composition for 12 substances [FL-no: 02.011, 02.012, 02.027, 
02.029, 05.020, 05.021, 05.148, 08.036, 08.044, 08.055, 08.079 and 09.273] have been provided since 
the first publication of FGE.72. 
The Panel concluded that the 23 substances are structurally related to the group of branched- and 
straight-chain unsaturated carboxylic acids and esters of these with aliphatic saturated alcohols 
evaluated by EFSA in the Flavouring Group Evaluation 05, Revision 2 (FGE.05Rev2).  
The Panel concluded, based on the genotoxicity data available for substances in FGE.05Rev2 and 
substances [FL-no: 05.020, 05.124 and 09.931] (FGE.202 and FGE.207), that  genotoxicity is not of 
concern for any of the 23 substances in FGE.72Rev1. 
The Panel agrees with the way the application of the Procedure has been performed by the JECFA for 
the 23 substances considered in this FGE. 
For all 23 substances use levels are needed to calculate the mTAMDI in order to identify those 
flavouring substances that need more refined exposure assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the 23 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity are available for all 23 JECFA-evaluated 
substances.  
Thus, for all 23 JECFA-evaluated aliphatic branched-chain saturated and unsaturated alcohols, 
aldehydes, acids and related esters [FL-no: 02.011, 02.012, 02.027, 02.029, 02.058, 02.076, 02.109, 
05.020, 05.021, 05.124, 05.148, 05.169, 08.036, 08.044, 08.047, 08.055, 08.064, 08.070, 08.079, 
09.273, 09.408, 09.931 and 16.001], the Panel agrees with JECFA conclusion “No safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 2008
4
 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5
. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6
. 
EFSA has evaluated 11 flavouring substances, which correspond to subgroup 1.1.2 of FGE.19, in its 
evaluation of the flavouring group 201 (FGE.201). The opinion was adopted on 25 September 2008. 
EFSA concluded that a genotoxic potential of the 11 α,β-unsaturated aldehydes and alcohol and 
related esters in the present FGE.201 could not be ruled out. 
Information on one representative material 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] 
has now been submitted by the European Flavour Association. This information is intended to cover 
also the re-evaluation of the following four substances from FGE.19 subgroup 2.1 (FGE.207): 
 12-beta-Santalen-14-ol [FL-no: 02.216] 
 12-alpha-Santalen-14-ol [FL-no: 02.217] 
 Santalyl acetate [FL-no: 09.034] 
 Santalyl phenylacetate [FL-no: 09.712]  
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following five substances: 12-beta-santalen-14-ol [FL-no: 02.216], 12-alpha-
santalen-14-ol [FL-no: 02.217], santalyl acetate [FL-no: 09.034], santalyl phenylacetate [FL-no: 
09.712] and 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] in accordance with 
Commission Regulation (EC) No 1565/2000. 
INTERPRETATION OF THE TERMS OF REFERENCE  
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931], first allocated to FGE.201, has 
subsequently been transferred to FGE.207 for evaluation with respect to genotoxicity. Based on the 
new genotoxicity data submitted, the Panel concluded that [FL-no: 09.931] does not give rise to 
concern with respect to genotoxicity and can accordingly now be evaluated through the Procedure in 
FGE.72Rev1. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and  
 certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No  
 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p.34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting  
 the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the  
 Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and  
 repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p 1-
161. 
6  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an  
 evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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Therefore, the European Commission request EFSA to carry out a safety assessment for  2,6-dimethyl-
2,5,7-octatriene-1-ol acetate [FL-no: 09.931] in accordance with Commission Regulation (EC) No 
1565/2000.
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the Opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65
th
 meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram (µg)/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
Flavouring Group Evaluation 72, Revision 1 
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information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the Evaluation of the Substances in the Present FGE  
The JECFA has evaluated a group of 32 flavouring substances consisting of aliphatic branched-chain 
saturated and unsaturated alcohols, aldehydes, acids and related esters. 
In FGE.72, which covered 22 of the 32 JECFA-evaluated substances, the Panel agrees with JECFA 
conclusion “No safety concern at estimated levels of intake as flavouring substances” based on the 
MSDI approach, for 10 substances [FL-no: 02.058, 02.076, 02.109, 05.124, 05.169, 08.047, 08.064, 
08.070, 09.408 and 16.001], and for the remaining 12 substances [FL-no: 02.011, 02.012, 02.027, 
02.029, 05.020, 05.021, 05.148, 08.036, 08.044, 08.055, 08.079 and 09.273], the Panel had 
reservations (no European production volumes available, preventing them to be evaluated using the 
Procedure, and/or missing data on composition and/or isomerism). 
FGE Opinion adopted Link No. of 
substances 
FGE.72 25 November 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1402.htm  22 
FGE.72Rev1 25 September 2013  23 
 
The Panel concluded in FGE.207 (EFSA CEF Panel, 2013) that [FL-no: 09.931] does not give rise to 
concern with respect to genotoxicity and can accordingly now be evaluated through the Procedure in 
FGE.72Rev1. 
Flavouring Group Evaluation 72, Revision 1 
 
EFSA Journal 2013;11(10):3392 9 
The present revision of FGE.72 (FGE.72Rev1) includes also the evaluation of new information which 
has become available since the publication of the first version of FGE.72. European production 
volumes have been provided (EFFA, 2010) for the two substances [FL-no: 05.148 and 08.079] and for 
12 substances [FL-no: 02.011, 02.012, 02.027, 02.029, 05.020, 05.021, 05.148, 08.036, 08.044, 
08.055, 08.079 and 09.273] from previous version, additional information on stereoisomerism has 
been submitted (EFFA, 2010; EFFA, 2013). 
2. Presentation of the Substances in the JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA Status 
The JECFA has evaluated a group of 32 flavouring substances consisting of aliphatic branched-chain 
saturated and unsaturated alcohols, aldehydes, acids and related esters at the 61
st
 meeting (JECFA, 
2004a; JECFA, 2004b). 
2.1.2. EFSA Considerations 
Fifteen of the 32 JECFA-evaluated substances were directly allocated to FGE.72. 
Seventeen of the 32 JECFA evaluated substances are α,β-unsaturated aldehydes and alcohols and 
related esters. As the α,β-unsaturated structures of these aldehydes and alcohols and related esters are 
considered to be structural alerts for genotoxicity (EFSA, 2008), these substances have been given 
special considerations. 
Possible genotoxicity of seven of the 17 α,β-unsaturated aldehydes and alcohols and related esters 
[FL-no: 02.012, 02.029, 02.058, 02.109, 05.020, 05.124 and 05.148] have been considered in FGE.202 
(EFSA, 2009b). The Panel concluded that although the substances in FGE.202 have a structural alert 
for genotoxicity, the data available on one of the substances, citral [FL-no: 05.020], made it possible to 
conclude that there would be no safety concern with respect to genotoxicity for these substances and 
that they accordingly could be evaluated through the Procedure in FGE.72.  
The genotoxicity of nine of the remaining ten α,β-unsaturated substances [FL-no: 05.033, 05.090, 
05.095, 05.105, 05.107, 05.126, 05.178, 09.177 and 09.931] have been evaluated in FGE.201 (EFSA, 
2009a). For these substances the Panel concluded that they could not be evaluated through the 
Procedure on the basis of the data available and concluded that there is a need for additional data 
before the substances can be re-evaluated. For the substance 2,6-dimethyl-2,5,7-octatriene-1-ol acetate 
[FL-no: 09.931], additional genotoxicity data submitted by the Industry (EFFA, 2012) have been 
evaluated by the Panel in FGE.207 (EFSA CEF Panel, 2013). Based on these data the Panel concluded 
that 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] does not give rise to concern with 
respect to genotoxicity and accordingly can be evaluated through the Procedure in FGE.72Rev1. As 
for the remaining one substance [FL-no: 05.114], which is considered in FGE.200 (EFSA CEF Panel, 
2011), a final conclusion as to its genotoxic properties is not yet available. Accordingly, the eight 
substances [FL-no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.178 and 09.177] from 
FGE.201 and the one substance [FL-no: 05.114] from FGE.200 will not be considered in this revision 
of FGE.72.  
This consideration therefore deals with 23 of the 32 JECFA-evaluated substances. 
The Panel concluded that the 23 aliphatic branched-chain saturated and unsaturated alcohols, 
aldehydes, acids and related esters evaluated by the JECFA are structurally related to the group of 
branched- and straight-chain unsaturated carboxylic acids and esters of these with aliphatic saturated 
alcohols evaluated by EFSA in the Flavouring Group Evaluation 05, Revision 2 (FGE.05Rev2) (EFSA 
CEF Panel, 2010). 
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2.2. Isomers 
2.2.1. Status 
The following seven substances [FL-no: 02.011, 02.027, 02.076, 05.021, 08.036, 08.047 and 08.079] 
in the group of the JECFA evaluated aliphatic branched-chain saturated and unsaturated alcohols, 
aldehydes, acids and related esters, have a chiral centre and the following 11 substances [FL-no: 
02.012, 02.029, 02.058, 05.020, 05.148, 08.044, 08.055, 08.064, 09.273, 09.408 and 09.931] can exist 
as geometrical isomers. 
2.2.2. EFSA Considerations 
The information about the stereoisomerism were inadequate for 13 of the substances [FL-no: 02.011, 
02.012, 02.027, 02.029, 05.020, 05.021, 05.148, 08.036, 08.044, 08.055, 08.079, 09.273 and 09.931] 
The Industry has submitted additional information for the 13 substances (EFFA, 2010; EFFA, 2013). 
The Panel concluded based on these data that the information provided on the stereoisomeric 
composition is adequate for all the substances. 
2.3. Specifications 
2.3.1. Status 
The JECFA specifications are available for all substances (JECFA, 2003) (See Table 1). 
2.3.2. EFSA Considerations 
The specifications are considered adequate for all 23 substances.  
3. Intake Estimation 
3.1. Status 
For all 23 substances evaluated through the JECFA Procedure intake data are available for the EU, see 
Table 8. 
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
02.011 
1219 
Citronellol 
 
2309 
59 
106-22-9 
Liquid 
C10H20O 
156.27 
Slightly soluble 
Soluble 
225 
 
IR 
90 % 
1.454-1.462 
0.850-0.860 
Racemate. Min. Assay 
value 90 %. Other 
constituents: di-
unsaturated and saturated 
C10 alcohols, citronellyl 
acetate, citronellal 
(EFFA, 2010). 
02.012 
1223 
Geraniol 
 
2507 
60 
106-24-1 
Liquid 
C10H18O 
154.25 
Slightly soluble 
Soluble 
230 
 
IR 
88 % 
1.469-1.478 
0.870-0.885 
The name Geraniol 
specifies the (Z)-isomer 
(EFFA, 2010). 
According to JECFA: 
Min. Assay value is ”88 
(total alcohols as 
C10H18O)” and 
secondary components 
”citronellyl, neryl, and 
geranyl acetate esters”. 
02.027 
1222 
Rhodinol 
 
2980 
76 
6812-78-8 
Liquid 
C10H20O 
156.27 
Insoluble 
Soluble 
132-135 (5 hPa) 
 
IR 
82 % 
1.463-1.473 
0.860-0.880 
Register name to be 
changed to (-)-Rhodinol 
(EFFA, 2010). 
According to JECFA: 
Min. assay value is ”82 
(total alcohols as 
C10H20O)” and 
secondary components 
”naturally occurring 
terpenoid esters - 
citronellyl, neryl, and 
geranyl acetate esters”. 
02.029 
1230 
3,7,11-Trimethyldodeca-
2,6,10-trien-1-ol  
2478 
78 
4602-84-0 
Liquid 
C15H26O 
222.37 
Insoluble 
Soluble 
263 
 
IR 
96 % 
1.487-1.492 
0.884-0.889 
Mixture of (Z)- and (E)-
isomers for both C=C 
double bonds (EFFA, 
2010). 10-15 %( 2Z,6Z); 
20-25 % (2E,6Z); 20-25 
% (2Z,6E); 40-50 % 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
(2E,2E) (EFFA, 2013). 
02.058 
1224 
Nerol 
 
2770 
2018 
106-25-2 
Liquid 
C10H18O 
154.25 
Insoluble 
Soluble 
227 
 
IR 
95 % 
1.467-1.478 
0.875-0.880 
Register name to be 
changed to (Z)-Nerol. 
According to JECFA: 
Min. assay value is ”95 
% (of total alcohols as 
C10H18O)”. 
02.076 
1199 
2-Methylbutan-1-ol 
 
3998 
2346 
137-32-6 
Liquid 
C5H12O 
88.15 
Very slightly 
soluble 
Soluble 
130 
 
IR NMR MS 
99 % 
1.409-1.412 
0.815-0.820 
Racemate. 
02.109 
1200 
3-Methylbut-2-en-1-ol 
 
3647 
11795 
556-82-1 
Liquid 
C5H10O 
86.10 
Insoluble 
Soluble 
140 
 
IR NMR MS 
99 % 
1.438-1.448 
0.844-0.852 
 
 
05.020 
1225 
Citral 
 
2303 
109 
5392-40-5 
Liquid 
C10H16O 
152.24 
Very slightly 
soluble 
Soluble 
228 
 
IR 
96 % 
1.486-1.490 
0.885-0.891 
Mixture of (Z)- and (E)-
isomer (EFFA, 2010). 
CASrn in Register does 
not specify 
stereoisomeric 
composition. 
05.021 
1220 
Citronellal 
 
2307 
110 
106-23-0 
Liquid 
C10H18O 
154.25 
Insoluble 
Soluble 
206 
 
IR 
85 % 
1.446-1.456 
0.850-0.860 
Racemate. Secondary 
components: 1,8-cineole, 
2-isopropylidene-5-
methylcyclohexanol, 
linalool and citronellyl 
acetate (EFFA, 2010). 
05.124 
1202 
3-Methylcrotonaldehyde 
 
3646 
10354 
107-86-8 
Liquid 
C5H8O 
84.11 
Slightly soluble 
Soluble 
133-135 
 
IR NMR 
99 % 
1.458-1.464 
0.870-0.875 
 
 
05.148 
1228 
Farnesal 
 
4019 
 
19317-11-4 
Liquid 
C15H24O 
220.36 
Insoluble 
Soluble 
198-201 (10hPa) 
 
IR NMR MS 
99 % 
1.494-1.504 
0.890-0.900 
Mixture of (Z)- and (E)-
isomer for both C=C 
double bonds (EFFA, 
2010). 10-15 % (2Z,6Z); 
20-25 % (2E,6Z); 20-25 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
% (2Z,6E); 40-50 % 
(2E,2E) (EFFA, 2013). 
05.169 
1229 
12-Methyltridecanal 
 
4005 
 
75853-49-5 
Liquid 
C14H28O 
212.38 
Insoluble 
Soluble 
141-143 (5 hPa) 
 
IR NMR MS 
97 % 
1.445-1.455 
0.930-0.941 
 
 
08.036 
1221 
Citronellic acid 
 
3142 
616 
502-47-6 
Liquid 
C10H18O2 
170.25 
Insoluble 
Soluble 
121-122 (1 hPa) 
 
NMR 
90 % 
1.455-1.462 
0.920-0.926 (20°) 
Racemate. Min. assay 
value (90 %). Other 
main constituents: 
citronellal; citronellyl 
acetate, nerol and 
geraniol (EFFA, 2010). 
08.044 
1211 
2,4-Dimethylpent-2-
enoic acid 
 
3143 
744 
21016-46-6 
Liquid 
C7H12O2 
128.17 
Very slightly 
soluble 
Soluble 
133-134 (20hPa) 
 
NMR 
92 % 
1.459-1.467 
0.991-0.999 
(E)-isomer (92 %), other 
const. 4-methyl-2-
methylenevaleric acid 
(EFFA, 2010). Register 
name to be changed to 
(2E),4-Dimethylpent-2-
enoic acid. According to 
JECFA: Min. Assay 
value ”92 (sum of 
isomers)” and secondary 
components ”4-methyl-
2-methylenevaleric 
acid”. 
08.047 
1212 
2-Methylheptanoic acid 
 
2706 
2003 
1188-02-9 
Liquid 
C8H16O2 
144.21 
Very slightly 
soluble 
Soluble 
121-122 (17hPa) 
 
NMR 
97 % 
1.420-1.427 
0.899-0.905 
Racemate. 
08.055 
1210 
2-Methyl-2-pentenoic 
acid 
 
3195 
11680 
3142-72-1 
Liquid 
C6H10O2 
114.14 
Slightly soluble 
Soluble 
123-125 (39hPa) 
 
IR 
98 % 
1.450-1.460 
0.976-0.982 
Mixture of (Z)- and (E)-
isomer (EFFA, 2010). 
CASrn in Register does 
not specify 
stereoisomeric 
composition. 60-75 % 
(E) and 20-30 % (Z) 
(EFFA, 2013). 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
08.064 
1205 
2-Methylcrotonic acid 
 
3599 
10168 
80-59-1 
Solid 
C5H8O2 
100.10 
Slightly soluble 
Soluble 
n.a. 
61-67 
MS 
99 % 
n.a. 
n.a. 
Register name to be 
changed to (2E)-
Methylcrotonic acid. 
08.070 
1204 
3-Methylcrotonic acid 
 
3187 
10138 
541-47-9 
Solid 
C5H8O2 
100.12 
Soluble 
Soluble 
 
70 
MS 
98 % 
n.a. 
n.a. 
 
08.079 
1218 
4-Ethyloctanoic acid 
 
3800 
 
16493-80-4 
Liquid 
C10H20O2 
172.27 
Slightly soluble 
Soluble 
110 (1 hPa) 
 
IR NMR 
99 % 
1.430-1.439 
0.898-0.908 
Racemate (EFFA, 2010). 
09.273 
1206 
Isobutyl crotonate 
 
3432 
10706 
589-66-2 
Liquid 
C8H14O2 
142.20 
Slightly soluble 
Soluble 
171 
 
IR 
95 % 
1.426-1.430 
0.880-0.900 
Mixture of (Z)- and (E)-
isomer (EFFA, 2010). 
CASrn in Register does 
not specify 
stereoisomeric 
composition. 70-85 % 
(E) and 10-35 % (Z) 
(EFFA, 2013). 
09.408 
1213 
Isobutyl 2-methylbut-
2(cis)-enoate 
 
2180 
247 
7779-81-9 
Liquid 
C9H16O2 
156.23 
Insoluble 
Soluble 
176-177 
 
IR NMR 
98 % 
1.438-1.446 
0.874-0.880 
 
 
09.931 
1226 
2,6-Dimethyl-2,5,7-
octatriene-1-ol acetate 
 
3886 
 
999999-91-
4 
Liquid 
C12H18O2 
194.28 
Insoluble 
Soluble 
70 (3 hPa) 
 
MS 
95 % 
1.490-1.500 
0.937-0.947 
According to JECFA: 
Min. assay value is 96 % 
(sum of isomers). 14-20 
% (2Z,5Z); 33-40 % 
(2Z,5E); 14-19 % 
(2E,5Z); 26-33 % 
(2E,5E) (EFFA, 2013). 
CASrn to be changed to: 
197098-61-6. 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
16.001 
1203 
Ammonium isovalerate 
 
2054 
464 
7563-33-9 
Solid 
C5H13O2N 
119.16 
Soluble 
Soluble 
n.a. 
72 
NMR 
98 % 
n.a. 
n.a. 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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4. Genotoxicity Data 
4.1. Genotoxicity Studies – Text Taken7 from the JECFA Report (JECFA, 2004b) 
In vitro 
No evidence of mutagenicity was reported in standard or modified (pre-incubation method) Ames 
assays when dl-citronellol [FL-no: 02.011] (up to 85 µg/plate), citronellal [FL-no: 05.021] (up to 500 
µg/plate), geraniol [FL-no: 02.012] (up to 889 µg/plate), citral [FL-no: 05.020] (up to 700 µl/plate) 
and farnesol [FL-no: 02.029] (Register name 3,7,11-trimethyldodeca-2,6,10-trien-1-ol) (up to 5000 
µl/plate) were incubated with Salmonella typhimurium strains TA92, TA94, TA97a, TA98, TA100, 
TA102, TA1535, and/or TA1537 with and without metabolic activation (Rockwell and Raw, 1979; 
Eder et al., 1980; Florin et al., 1980; Kasamaki et al., 1982; Lutz et al., 1982; Ishidate et al., 1984; 
Zeiger et al., 1987; Creutziger, 1989; Gomes-Carneiro et al., 1998; NTP, 2003). Negative results were 
reported in a mutation test in which 100 µg/plate of citral was incubated with Escherichia coli WP2 
uvrA (Yoo, 1986).  
Citronellal [FL-no: 05.021] and geraniol [FL-no: 02.012] did not induce sister chromatid exchanges in 
Chinese hamster ovary cells in the absence of metabolic activation at concentrations up to 100 µmol/l 
(15.4 µg/ml) for citronellal and 333 µmol/l (51.4 µg/ml) for geraniol (Sasaki et al., 1989). In a non-
standard assay designed to maximise the frequency of chromosomal aberrations in a Chinese hamster 
B241 cell line, citronellal at concentrations of 0.008 µg/ml gave weakly positive results with and 
without metabolic activation (Kasamaki et al., 1982). No evidence of an increase in chromosomal 
aberrations was reported when geraniol [FL-no: 02.012] at concentrations of up to 125 µg/ml was 
incubated with Chinese hamster fibroblast cells in the absence of metabolic activation (Ishidate et al., 
1984), although there was an 8 % increase in polyploidy.  
Assays for sister chromatid exchanges with citral [FL-no: 05.020] were performed in Chinese hamster 
ovary cells. In the absence of metabolic activation, an increase in sister chromatid exchanges of at 
least 20 % that of control cultures was reported at concentrations of 0.289 - 2.89 µg/ml in the first trial 
and 7.5 - 10 µg/ml in the second trial. Toxicity was observed at 8.86 and 20 µg/ml in the first and 
second trial, respectively. With metabolic activation, an increase of sister chromatid exchanges of at 
least 20 % that of control cultures was reported with citral at 8.68 µg/ml in the first trial and 15.1 - 
40.2 µg/ml in the second trial. Toxicity was reported at 28.9 µg/ml in the first trial; no toxicity was 
observed in the second trial. Owing to cell cycle delay induced by citral, at the higher concentrations 
(10 µg/ml without and 20.1 - 40.2 µg/ml with metabolic activation) extended culture periods were 
necessary to allow accumulation of sufficient second-division metaphase cells for analysis (NTP, 
2003). In contrast to these findings, there was no evidence for an increase in chromosomal aberrations 
with higher concentrations of citral (12.5 - 25.3 µg/ml without and 30.3 - 60.6 µg/ml with metabolic 
activation) (NTP, 2003) or, in another chromosomal aberration assay in Chinese hamster fibroblast 
cells, at concentrations of citral of up to 30 µg/ml, without metabolic activation (Ishidate et al., 1984).  
Rec assays for DNA repair in Bacillus subtilis strains M45 and H17 have been performed with dl-
citronellol [FL-no: 02.011], citronellal [FL-no: 05.021], geraniol [FL-no: 02.012] and citral [FL-no: 
05.020]. In one study, each of the four agents gave negative results at concentrations of 16 or 17 
µg/disc (Oda et al., 1979). Citral gave positive results in two other rec assays (Kuroda et al., 1984; 
Yoo, 1986) but only at high concentrations (1110 and 2220 µg/disc). Rec assays performed at lower 
concentrations of citral (up to 560 µg/disc) were negative (Kuroda et al., 1984).  
In a recently developed assay for DNA damage measuring induction of p53 tumour suppressor protein 
in mouse fibroblasts (NTCT 929 cell line) in vitro, citral gave positive results at concentrations of 10 - 
30 µg/ml after 17 hours of incubation. In this assay, increased expression of p53 is considered to 
indicate the induction of DNA damage (Duerksen-Hughes et al., 1999). 
                                                     
7 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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In vivo 
Groups of four or five male B63CF1 mice received citral [FL-no: 05.020] at a dose of 250, 500, 750 
and 1000 mg/kg bw per day by intraperitoneal injection at 24-hour intervals for a period of 3 days. A 
group of animals given corn oil only and another group given cyclophosphamide were used as vehicle 
and positive controls, respectively. The highest dose of citral was lethal and only the three lower doses 
were used to evaluate the results of the assay. Twenty-four hours after the third injection, the animals 
were sacrificed and blood smears were taken from bone marrow cells collected from the femur. 
Scoring of 2000 polychromatic erythrocytes for formation of micronuclei revealed no increase in 
micronucleated polychromatic erythrocytes at any dose. The ratio of polychromatic erythrocytes 
(PCE) / normochromatic erythrocytes (NCE) was not determined (NTP, 2003).  
In addition to the assay for micronuclei formation in bone marrow, an assay for micronuclei formation 
in mouse peripheral blood erythrocytes was performed. Peripheral blood samples were obtained within 
24 hours of the final treatment in a 14-week study of toxicity in which female and male B63CF1 mice 
were given diet containing microencapsulated citral at a dose of up to 7550 and 8110 mg/kg bw per 
day, respectively. Blood smears were made, fixed and stained and 1000 NCEs per animal were scored 
for the frequency of micronuclei. In addition, the percentage of PCEs among the total population of 
erythrocytes was scored. Results for all doses in both males and females showed no increase in 
micronucleated NCEs or in the percentage of PCEs (NTP, 2003). 
Conclusion on genotoxicity 
Several aliphatic branched-chain unsaturated alcohols and aldehydes have been tested in the Ames 
assay and found to be not mutagenic in vitro. In addition to showing a lack of mutagenic potential in 
the Ames assay, citral gave negative results in assays for mutagenicity in E. coli WP2 uvrA. There was 
some evidence of DNA damage caused by citral from two rec assays with B. subtilis, but only at very 
high concentrations. Rec assays performed with lower concentrations of test substance, however, gave 
negative results for citral as well as for dl-citronellol, citronellal and geraniol.  
Citronellal showed weak evidence of clastogenicity in a non-standard assay for chromosomal 
aberrations, but gave negative results in assays for sister chromatid exchanges. Geraniol neither 
induced sister chromatid exchanges nor chromosomal aberrations. Citral showed evidence of activity 
in assays for sister chromatid exchanges, but increased incubation times were required because of 
delayed cell cycling. Citral did not induce chromosomal aberrations in vitro nor did it show signs of 
genotoxicity in assays for micronucleus formation in bone marrow and peripheral erythrocytes in vivo. 
Citral induced DNA damage in mouse fibroblasts in vitro, as shown by increased expression of P53. 
This result, however, contrasts with the results of existing assays for genotoxicity with citral, which 
are largely negative.  
On the basis of the results of available studies of genotoxicity, the Committee concluded that members 
of this group of aliphatic branched-chain saturated and unsaturated alcohols, aldehydes, acids and 
related esters are not genotoxic. 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA, see Table 2. 
4.2. Genotoxicity Studies – Text Taken8 from EFSA FGE.05Rev2 (EFSA CEF Panel, 2010) 
There are in vitro genotoxicity data for four candidate substances [FL-no: 09.375, 09.586, 09.647 and 
09.652] and for four supporting substances [FL-no: 08.013, 05.074 and a mixture of 09.646 and 
methyl linolenate]. In vivo data are available for two candidate substances [FL-no: 09.586 and 09.647] 
and for one supporting substance [FL-no: 05.074]. 
                                                     
8 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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Studies on candidate substances 
In vitro studies 
Methyl oleate [FL-no: 09.652], methyl methacrylate [FL-no: 09.647], ethyl methacrylate [FL-no: 
09.375] and isobutyl 2-methylprop-2-enoate [FL-no: 09.586] were reported to be non-mutagenic in 
standard, pre-incubation or liquid suspension protocol Ames assays including S. typhimurium strains 
TA97, TA98, TA100, TA1535, TA1537 and/or TA1538 with or without metabolic activation (Table 
3). In three instances, the results of Ames assays with methyl methacrylate were weakly positive; 
however, these results were accompanied by cytotoxicity.  
Methyl methacrylate and ethyl methacrylate have been tested in several mammalian cell assays (Table 
3). Positive results seen in chromosome aberrations, mouse lymphoma, Sister Chromatid Exchange 
(SCE), Hypoxanthine Phosphoribosyl Transferase (HPRT) and/or micronucleus assays in most 
instances were obtained at high exposure concentrations (i.e. > 10 mM or > 1000 µg/ml) and (when 
reported) high levels of cytotoxicity. However, when methyl methacrylate was tested in a mouse 
lymphoma assay at concentrations between 5 and 10 mM in the presence of S9-mix, it revealed a 
positive result which was accompanied by only low cytotoxicity (about 80 % survival at 5 mM and 
approximately 40 % at 10 mM) (Dearfield et al., 1991). 
In vivo studies 
Methyl methacrylate [FL-no: 09.647] was evaluated in a mouse micronucleus study conducted by oral 
gavage. The result was negative, however, it is not clear whether the substance had reached the bone 
marrow. Two sex-linked recessive lethal mutation studies (one by inhalation and the other by 
injection) in Drosophila melanogaster were negative, as was a dominant lethal assay in mice 
conducted via inhalation exposure. Rats exposed to high inhalation concentrations of methyl 
methacrylate did have weak, but statistically significant, increases in chromosome aberrations in bone 
marrow cells at some exposure levels in comparison to the negative control values both after single 
and multiple exposures. However, a clear conclusion cannot be drawn from these studies. SCE and 
chromosome aberration studies with peripheral lymphocytes from male workers occupationally 
exposed to methyl methacrylate by inhalation for eight hours/day were negative (Table 4). 
Isobutyl 2-methylprop-2-enoate [FL-no: 09.586] was evaluated in a mouse micronucleus study with 
oral doses as high as 5000 mg/kg bw. Results were reported to be negative. 
For methyl methacrylate, genotoxicity data were summarised the EU Risk Assessment Report (CEC, 
2002) as follows: 
“Methyl methacrylate was negative in bacterial gene mutation tests. From mammalian cell culture 
assays it may be concluded that methyl methacrylate is a high toxicity clastogen (i.e. induction of 
chromosomal aberrations is bound to highly toxic doses). The effect is not dependent on presence of 
S9-mix. These findings are in line with results from mouse lymphoma assays where positive findings 
seem to be due to the induction of small colonies. Marginal increases in SCE frequencies are of low 
significance.” 
“In vivo an oral mouse bone marrow micronucleus test was negative for doses up to 4520 mg/kg. No 
clear conclusion could be drawn from bone marrow chromosomal aberration assays with rats. A 
dominant lethal assay with male mice led to a negative result.” 
“In vitro methyl methacrylate has the potential for induction of mutagenic effects, esp. clastogenicity; 
however, this potential seems to be limited to high doses with strong toxic effects. Furthermore, the 
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negative in vivo micronucleus test and the negative dominant lethal assay indicate that this potential is 
probably not expressed in vivo." 
Studies on supporting substances 
In vitro studies 
No evidence of mutagenicity was reported for 2,6-dimethyl-5-heptenal [FL-no: 05.074], oleic acid 
[FL-no: 08.013], methyl linolenate [FL-no: 09.646] or methyl linoleate [FL-no: 09.645] in the 
standard or pre-incubation protocol Ames assay using S. typhimurium strains TA98, TA100, TA1535, 
TA1537, or TA1538 with or without the addition of metabolic activation (Shimizu et al., 1985; 
Mortelmans et al., 1986; Wild et al., 1983; Heck et al., 1989) (Table 3). The maximum doses reported 
for these studies ranged from 333 to 50000 µg/plate. In further bacterial assays, such as the rec-assay 
utilising B. subtilis, incubated with oleic acid (Osawa and Namiki, 1982), the His
+
 reversion assay 
utilising S. typhimurium incubated with methyl linoleate or methyl linolenate [FL-no: 09.646] 
(MacGregor et al., 1985) and a modified Ames test utilising E. coli WP2uvrA incubated with oleic 
acid (Shimizu et al., 1985), these aliphatic unsaturated non-conjugated acids and esters were non-
mutagenic. 
With respect to mammalian cell assays, rat hepatocytes were tested for unscheduled DNA synthesis 
(UDS) after exposure to concentrations of up to 1.0 mg 2,6-dimethyl-5-heptenal/ml [FL-no: 05.074] 
(Table 3). The results from this study showed no genotoxic effects (Heck et al., 1989). 
In vivo studies 
A bone marrow micronucleus test was conducted in vivo in mice with a maximum single dose of 1540 
mg/kg 2,6-dimethyl-5-heptenal [FL-no: 05.074]. All mice survived the treatment. There were no 
statistically significant increases in the incidence of micronucleated PCEs observed (Wild et al., 1983). 
However, the quality of the study is limited since only a single sampling time was used and the 
PCE/NCE ratio was not reported. Therefore, it is not clear whether the substance had reached the bone 
marrow. 
In the Basc test using D. melanogaster, 2,6-dimethyl-5-heptenal was negative when tested at a 
concentration of 25 mM (Wild et al., 1983). 
Conclusion on genotoxicity 
Genotoxicity data are available only for a limited number of substances and the genotoxicity could not 
be assessed adequately. However, the data available do not preclude the evaluation of the candidate 
substances using the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by the EFSA in FGE.05Rev2, see 
Tables 3 and 4. 
4.3. Genotoxicity Studies – Text Taken9 from EFSA FGE.202 (EFSA, 2009b) 
“There are in vitro and in vivo studies available on citral [FL-no: 05.020] and on 3-
methylcrotonaldehyde (3-methyl-2-butenal) [FL-no: 05.124]. 
3-Methylcrotonaldehyde was found mutagenic in a valid modified Ames test, i.e. the liquid suspension 
assay, both in the absence, and to a lower extent, in the presence of metabolic activation (S9-mix), in 
TA100 S. typhimurium strain (BASF, 1991). Of doubtful relevance was a slight increase (factor 2.1) in 
the number of revertants observed with TA98 strain, only in the absence of S9-mix at the highest 
                                                     
9 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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concentration (2500 µg/plate). It was found negative in a valid bone marrow micronucleus assay in 
mice, treated orally at 175, 350 and 750 mg/kg body weight, with signs of toxicity at the highest dose, 
as shown by the ratio of PCEs/NCEs (BASF, 1992). Moreover, it was found negative in a valid in vivo 
unscheduled DNA synthesis (UDS) assay, carried out on hepatocytes from rats treated orally at dose 
levels of 350 and 700 mg/kg body weight (BASF, 2001). In conclusion, based on the negative results 
in two valid in vivo assays (rat liver UDS and mouse bone marrow micronucleus), the positive result 
observed in the modified Ames test is considered of limited relevance for the overall evaluation. 
Therefore, for this substance, the Panel considers that genotoxicity is of no concern.  
Citral was not mutagenic in several valid Ames tests (Gomes-Carneiro et al., 1998; NTP, 2003; 
Ishidate et al., 1984; Zeiger et al., 1987) and it did not induce chromosome aberrations in a valid in 
vitro study with chinese hamster ovary (CHO) cells (NTP, 2003). Moreover, it was negative in a valid 
in vivo mouse bone marrow micronucleus assay (NTP, 2003). The positive results in an in vitro test 
for sister chromatid exchanges (SCE) (NTP, 2003) and in inappropriate test systems like the Rec assay 
in B. subtilis (Yoo, 1986; Kuroda et al., 1984) and the induction of the tumour suppressor protein p53 
(Duerksen-Hughes et al., 1999) are considered of limited relevance for the overall evaluation. The 
Panel concluded that for citral genotoxicity is not of concern. 
Overall, the Panel concluded that the genotoxicity data available do not give rise to concern for the 37 
substances in FGE.202 using the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by the EFSA in FGE.202, see Tables 
5 and 6 
Conclusion on Genotoxicity and Carcinogenicity 
Based on the available data, the Panel concluded that there would be no safety concern with respect to 
genotoxicity or carcinogenicity for the 37 α,β-unsaturated substances presented in this FGE.” 
4.4. Genotoxicity Studies – Text Taken10 from EFSA FGE.207 (EFSA CEF Panel, 2013) 
The new data submitted for 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] covers in vitro 
assays in bacteria and mammalian cell systems. 
In vitro Data 
Bacterial Reverse Mutation Assay 
An Ames assay was conducted in S. typhimurium strains TA98, TA100, TA1535, TA1537 and TA102 
to assess the mutagenicity of 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931], both in the 
absence and in the presence of metabolic activation by S9-mix (from livers of rats induced with 
Aroclor 1254), in three experiments (King, 2000). An initial experiment was carried out in the absence 
and presence of S9-mix in the five strains, using final concentrations of 2,6-dimethyl-2,5,7-octatriene-
1-ol acetate at 5 - 5000 μg/plate in the presence of S9-mix activation and 5 - 1500 μg/plate in the 
absence of S9-mix, plus negative (solvent) and positive controls. The standard plate incorporation 
assay was used. Evidence of toxicity, in terms of a decrease in revertant count, was apparent on all 
plates treated at 500 μg/plate and above in the absence of S9-mix. In the presence of S9-mix, the test 
article was toxic at concentrations of 1500 μg/plate and above for strains TA1537 and TA102, and at 
5000 μg/plate for strains TA98, TA100 and TA1535. In all cases revertant counts were obtained from 
at least four different concentrations, so these data were considered valid for mutation assessment. In 
the absence of S9-mix activation, no statistically significant increases in revertant numbers were 
observed in any of the test strains. In the presence of S9-mix activation no statistically significant 
increases in revertant numbers were observed for strains TA98, TA100, TA1535 or TA1537, but very 
                                                     
10 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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small increases in revertant numbers were observed in strain TA102 at 15 and 50 μg/plate which, 
although statistically significant (p ≤ 0.05), amounted to only 1.17-fold and 1.18-fold increases over 
background, respectively. Furthermore, no increases were observed at the higher test concentrations of 
150 and 500 μg/plate. 
In a second confirmatory experiment using the same conditions, no statistically significant increases in 
revertant numbers were observed at any concentration in any of the strains, either in the presence or 
absence of S9-mix activation. To further investigate the potential mutagenic effect in strain TA102 in 
the presence of S9-mix activation, a third experiment was conducted in that strain only. No 
statistically significant increases in revertant numbers were observed at any concentration tested. 
On this basis, the very small increases seen in only a single experiment at the two lower test 
concentrations in the presence of S9-mix activation in strain TA102 were not reproducible or 
concentration-related and were therefore considered to be chance occurrences and not related to 
treatment with 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] (King, 2000). It was 
concluded that 2,6-dimethyl-2,5,7-octatriene-1-ol acetate did not induce mutation in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. typhimurium when tested under 
the conditions of this study. These conditions included treatments at concentrations up to either the 
limit of toxicity or 5000 μg/plate (the maximum recommended concentration, according to current 
regulatory guidelines), in the absence and in the presence of a rat liver metabolic activation system 
(S9-mix). 
Micronucleus Assay 
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] was assayed for the induction of 
chromosome damage and potential aneugenicity in mammalian cells in vitro by examining the effect 
of compound treatment on the frequency of micronuclei in cultured human peripheral blood 
lymphocytes (whole blood cultures pooled from two healthy male volunteers in two separate 
experiments) treated in the absence and presence of a metabolising system (S9-mix) from livers of rats 
induced with Aroclor 1254 (Whitwell, 2012). 
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate was added at 48 hours following culture initiation 
(stimulation by phytohaemagglutinin) either for 3 hours treatment in the absence or presence of S9-
mix plus 21 hours recovery, or for 24 hours treatment in the absence of S9-mix without recovery. 
Cytochalasin B (6 μg/ml) was added at the start of the 24-hour continuous treatment, or at the start of 
the 21-hour recovery periods following the 3-hour treatments, in order to block cytokinesis and 
generate binucleate cells for analysis. It remained in the cultures until they were harvested 24 hours 
after the start of treatment. A preliminary range-finding experiment had been conducted with and 
without S9-mix treatment in order to determine the effect of treatment upon Replication Index (RI), 
which was used as a basis for choosing a range of concentrations to be evaluated in Experiments 1 and 
2. 
In all of the different treatment conditions and separate experiments, frequencies of micronucleated 
binucleate cells (MNBN) were normal in negative controls and were significantly increased by 
treatment with the positive control chemical. 
In Experiment 1, all three different treatment conditions described above were investigated. In the first 
treatment condition, 2,6-dimethyl-2,5,7-octatriene-1-ol acetate was added for 3 hours in the absence of 
S9-mix at concentrations of 70, 85, 100 or 120 μg/mL along with positive and negative controls, 
followed by 21 hours recovery. No significant increases in the frequency of MNBN were observed 
relative to concurrent vehicle controls at any of the concentrations analysed. Furthermore, the MNBN 
cell frequencies in all treated cultures under this treatment condition fell within the 95
th
 percentile of 
the normal range. 
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In the second treatment condition, following 24 hours continuous treatment at 20, 40 or 60 μg/mL in 
the absence of S9-mix without recovery, no increases in the frequency of MNBN cells were obtained 
that were significantly higher (p ≤ 0.05) than those observed in concurrent controls. Furthermore, the 
MNBN cell frequencies in all treated cultures under this treatment condition fell within the 95
th
 
percentile of the normal range. 
In the third treatment condition, following 3 hours treatment with 2,6-dimethyl-2,5,7-octatriene-1-ol 
acetate at concentrations of 120, 140, 180 or 225 μg/mL in the presence of S9-mix, followed by 21 
hours recovery, the frequency of MNBN cells were significantly higher (p ≤ 0.05) than concurrent 
controls at the top concentration analysed. This concentration induced a 57 % mean level of 
cytotoxicity, which is close to the recommended upper limit for this test procedure. Furthermore, 
increases in the frequency of MNBN cells were only seen in one replicate (A) where only 394 
binucleate cells could be analysed for this test concentration, where cytotoxicity actually exceeded 60 
%, and where examination of the slides indicated a concentration-related effect on cells without intact 
cytoplasm. This may have resulted in an underestimation of the cytotoxicity, but it was not observed in 
the other replicate culture (B). 
In Experiment 2, the weak induction of micronuclei that was observed in Experiment 1 in the presence 
of S9-mix was further investigated. Following treatment for 3 hours followed by 21 hours recovery in 
the presence of S9-mix with 2,6-dimethyl-2,5,7-octatriene-1-ol acetate at concentrations of 119.2, 180, 
250 or 290 μg/mL, which induced 5 %, 19 %, 39 % and 54 % cytotoxicity, respectively, small but 
statistically significant (p ≤ 0.05) increases in MNBN cell frequencies were observed at the lowest and 
highest concentrations analysed. At the highest concentration analysed only a single replicate culture 
gave MNBN cell frequencies that exceeded normal historical control values and it is also noteworthy 
that the vehicle control frequency was quite low for this particular experiment which might have 
contributed to the test outcome. Furthermore, additional analysis of spare slides from the replicate 
cultures at the lowest and highest concentrations analysed resulted in the overall micronucleus 
frequencies falling within normal ranges. On this basis, the weak statistical significance observed in 
the first experiment was not reproduced at higher concentrations and similar levels of toxicity and was 
therefore not considered to be of biological relevance. 
In conclusion, 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] was not considered to 
demonstrate induction of micronuclei in a robust study that achieved required levels of toxicity 
(Whitwell, 2012). 
Conclusion 
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] did not induce any biologically significant 
increases in bacterial mutation when evaluated in an Ames test in the presence and absence of S9 
metabolic activation. It did induce weak genotoxic effects in the in vitro micronucleus assay in an 
initial experiment in the presence of S9-mix at the highest concentration only. In a second experiment, 
although statistically significant increases were observed at the lowest and highest concentrations 
tested, these increases fell within the historical control range for the testing laboratory, and were not 
considered to be biologically important. The Panel therefore concluded that 2,6-dimethyl-2,5,7-
octatriene-1-ol acetate [FL-no: 09.931], from subgroup 1.1.2 of  FGE.19 (FGE.201), does not give rise 
to concern with respect to genotoxicity and can accordingly be evaluated through the Procedure. 
Furthermore, as 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] is considered 
representative for the four precursors for α,β-unsaturated alicyclic aldehydes [FL-no: 02.216, 02.217, 
09.034 and 09.712] from subgroup 2.1 of FGE.19 (FGE.207), the genotoxicity concern can also be 
lifted for these four substances and accordingly they can also be evaluated through the Procedure as 
well (in FGE.12Rev4 and FGE.73Rev2). 
For a summary of in vitro / in vivo genotoxicity data considered by the EFSA in FGE.207, see Table 7. 
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4.5. EFSA Considerations 
The Panel concluded, based on the genotoxicity data available for substances in FGE.05Rev2 and 
substances [FL-no: 05.020, 05.124 and 09.931] (FGE.202 and FGE.207) that  genotoxicity is not of 
concern  for all the 23 substances in FGE.72Rev1. 
5. Application of the Procedure 
5.1. Application of the Procedure to 23 Aliphatic Branched-chain Saturated and 
Unsaturated Alcohols, Aldehydes, Acids and related Esters by JECFA (JECFA, 2004b) 
According to the JECFA all of the substances belong to structural class I, using the decision tree 
approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded 22 of the aliphatic branched-chain saturated and unsaturated alcohols, 
aldehydes, acids and related esters at step A3 in the JECFA Procedure – i.e. the substances are 
expected to be metabolised to innocuous products (step 2) and the intakes for all substances are below 
the thresholds for their structural class I (step A3). 
The remaining substance, citral [FL-no: 05.020], is not endogenous. The evaluation therefore 
proceeded to step A5. A NOAEL of 60 mg/kg bw from the carcinogenicity study (NTP, 2003) exists 
to provide an adequate margin of safety to the estimated intake as flavouring substance. 
In conclusion the JECFA evaluated all 23 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The stepwise evaluations of the 23 substances evaluated by the JECFA are summarised in Table 8. 
5.2. Application of the Procedure to 37 Branched- and Straight-chain Unsaturated 
Carboxylic Acids and Esters of These with Aliphatic Saturated Alcohols Evaluated by 
EFSA in FGE.05Rev2 (EFSA CEF Panel, 2010) 
Thirty-seven candidate substances were evaluated in FGE.05Rev2. Thirty-four substances are 
classified into structural class I and three substances into structural class II using the decision tree 
approach presented by Cramer et al. (Cramer et al., 1978). 
All 37 substances were concluded at step A3 – i.e. the substances are expected to be metabolised to 
innocuous products (step 2) and the estimated daily intake is below the threshold for the structural 
class (step A3).  
In conclusion the Panel evaluated all 37 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach.  
The stepwise evaluations of the 37 substances evaluated by the EFSA are summarised in Table 9. 
5.3. EFSA Considerations 
The Panel agrees with the way the application of the Procedure has been performed by the JECFA for 
all 23 substances in the group of aliphatic branched-chain saturated and unsaturated alcohols, 
aldehydes, acids and related esters.  
CONCLUSION 
The JECFA evaluated a group of 23 aliphatic branched-chain saturated and unsaturated alcohols, 
aldehydes, acids and related esters at the 61
st
 meeting.  
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The Panel concluded that the 23 substances are structurally related to the group of branched- and 
straight-chain unsaturated carboxylic acids and esters of these with aliphatic saturated alcohols 
evaluated by EFSA in the Flavouring Group Evaluation 05, Revision 2 (FGE.05Rev2).  
The Panel concluded, based on the genotoxicity data available for substances in FGE.05Rev2 and 
substances [FL-no: 05.020, 05.124 and 09.931] (FGE.202 and FGE.207), that  genotoxicity is not of 
concern  for all the 23 substances in FGE.72Rev1. 
The Panel agrees with the way the application of the Procedure has been performed by the JECFA for 
all 23 substances considered in this FGE. 
For all 23 substances use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the 23 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity are available for all 23 JECFA evaluated 
substances.  
Thus, for all 23 JECFA-evaluated aliphatic branched-chain saturated and unsaturated alcohols, 
aldehydes, acids and related esters [FL-no: 02.011, 02.012, 02.027, 02.029, 02.058, 02.076, 02.109, 
05.020, 05.021, 05.124, 05.148, 05.169, 08.036, 08.044, 08.047, 08.055, 08.064, 08.070, 08.079, 
09.273, 09.408, 09.931 and 16.001] the Panel agrees with JECFA conclusion “No safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach.
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SUMMARY OF GENOTOXICITY DATA  
Table 2:  Genotoxicity Data (in vitro / in vivo) evaluated by JECFA (JECFA, 2004b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
In vitro       
02.011 
1219 
Citronellol Reverse mutation S. typhimurium  
TA98 and TA100 
0.05 - 100 µl/plate 
(0.04 - 85 µg/plate) 
Negativea (Rockwell and Raw, 
1979) 
 
Rec assay B. subtilis 
M45 and H17 
17 µg/disk Negative (Oda et al., 1979) 
 
02.012 
1223 
Geraniol Reverse mutation S. typhimurium TA100 0.01 - 1.0 µl 
(8.89 - 889 mg/tube) 
Negativeb (Eder et al., 1980)  
S. typhimurium TA98, TA100, 
TA1535, TA1537 
3 µmol/plate 
(463 µg/plate) 
Negativeb (Florin et al., 1980)  
S. typhimurium TA92, TA94, 
TA98, TA100, TA1535, TA1537 
< 500 µg/plate Negativea (Ishidate et al., 1984)  
Sister chromatid exchange Chinese hamster ovary cells 33.3 - 333 µmol/l  
(5.14 - 51.4 µg/ml) 
Negativec (Sasaki et al., 1989)  
Chromosomal aberration Chinese hamster fibroblast cells < 125 µg/ml Negativec,d (Ishidate et al., 1984)  
Rec assay B. subtilis M45 and H17 16 µg/disk Negative 
(Oda et al., 1979)  
02.029 
1230 
3,7,11-Trimethyldodeca-
2,6,10-trien-1-ol 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537 
8 - 5000 µg/plate Negativeb (Creutziger, 1989)  
S. typhimurium TA98, TA100, 
TA1535, TA1537 
3 µmol/plate (667 µg/plate)e Negativeb 
(Florin et al., 1980)  
05.020 
 
Citral 
 
Reverse mutation 
 
S. typhimurium TA98, TA100, 
TA97a, TA102 
5 - 700 µg/plate Negativeb (Gomes-Carneiro et al., 
1998) 
 
S. typhimurium TA92, TA94, 
TA98, TA100, TA1535, TA1537 
Up to 100 µg/plate Negativea (Ishidate et al., 1984) 
 
S. typhimurium TA100 NR Negativeb (Lutz et al., 1982) 
S. typhimurium TA98, TA100, 1 - 160 µg/plate Negativeb (Zeiger et al., 1987)  
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Table 2:  Genotoxicity Data (in vitro / in vivo) evaluated by JECFA (JECFA, 2004b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
TA1535, TA1537 (NTP, 2003) 
 
Mutation E. coli WP2uvrA (trp-) 13 - 100 µg/plate Negative (Yoo, 1986) 
 
Sister chromatid exchange Chinese hamster ovary cells 0.289 - 40.2 µg/ml Positiveb (NTP, 2003) 
 
Chromosomal aberration 
 
Chinese hamster ovary cells 12.5 - 60.6 µg/ml Negativeb (NTP, 2003) 
 
Chinese hamster fibroblast cells Up to 30 µg/ml Negativec (Ishidate et al., 1984) 
 
Rec assay 
 
B. subtilis M45 and H17 17 µg/disk Negative (Oda et al., 1979) 
 
B. subtilis M45 and H17 0.16, 0.32, 0.63 µl/disk 
(142, 284, 560 µg/disk) 
1.25, 2.5 µl/disk 
(1110, 2220 µg/disk) 
Negative 
 
Positive 
(Kuroda et al., 1984) 
 
B. subtilis M45 and H17 < 2.5 µl/disk 
(< 2220 µg/disk) 
Positive (Yoo, 1986) 
 
Induction of tumour suppressor 
protein p53 (DNA damage) 
Mouse fibroblast cells (NTCT 
929) 
10 - 30 µg/ml Positive (Duerksen-Hughes et al., 
1999) 
 
05.021 
1220 
Citronellal Reverse mutation 
 
S. typhimurium  
TA98, TA100, TA97a, TA102 
1 - 300 µg/plate Negativeb (Gomes-Carneiro et al., 
1998) 
 
S. typhimurium  
TA98 and TA100 
0.05 - 500 µg/plate Negativeb (Kasamaki et al., 1982) 
 
Sister chromatid exchange Chinese hamster ovary cells 3.3 - 100 µmol/l 
(0.51 - 15.4 µg/ml) 
Negativec (Sasaki et al., 1989) 
 
Chromosomal aberration Chinese hamster B241 cells 50 nmol/l 
(0.008 µg/ml) 
Positiveb (Kasamaki et al., 1982) 
 
Rec assay B. subtilis  17 µg/disk Negative (Oda et al., 1979) 
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Table 2:  Genotoxicity Data (in vitro / in vivo) evaluated by JECFA (JECFA, 2004b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
M45 and H17  
In vivo 
05.020 
1225 
Citral 
 
Micronucleus formation Mouse bone marrow erythrocytes 250, 500 or 750 mg/kg bwf Negative (NTP, 2003)  
Mouse peripheral blood 
erythrocytes 
 
745, 1840, 3915 or 8110 
mg/kg bw per day (males)g 
Negative (NTP, 2003)  
790, 1820, 3870 or 7550 
mg/kg bw per day 
(females)g 
Negative (NTP, 2003) 
a With metabolic activation. 
b With and without metabolic activation. 
c Without metabolic activation. 
d Polyploidy (8 %) was observed at the highest dose tested. 
e Substance precipitated on the plate. 
f Three intraperitoneal injections given at 24-hour intervals; male mice only. 
g Microencapsulated citral was administered in the diet for 14 weeks. 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.05Rev2 (EFSA CEF Panel, 2010) 
Chemical Name  
[FL-no] 
Test System Test Object Concentration Result Reference Comments 
(Oleic acid [08.013]) Ames  S. typhimurium TA1535, 
TA1537, TA98, TA100, 
TA1538. E. coli 
5000 µg/plate Negative1 (Shimizu et al., 1985) Modified Ames, reincubation. 
S. typhimurium TA1535, 
TA98, TA100, TA1537 
333 µg/plate Negative1 (Mortelmans et al., 
1986) 
Modified Ames, reincubation. 
Rec assay B. subtilis 1.0 mg/plate Negative1 (Osawa and Namiki, 
1982) 
 
Sister Chromatid 
Exchange 
CH V79 2.5 - 10 µg/ml Negative (Kinsella, 1982)  
Chromosome 
aberrations 
CH V79 2.5 - 10 µg/ml Positive (Kinsella, 1982) No data on cytotoxicity reported. 
6-TG resistance CH V79 1.0 µg/ml Negative (Kinsella, 1982)  
Methyl oleate [09.652]  Ames S. typhimurium TA97, 
TA98, TA100, TA1535, 
TA1537 
0.100, 0.333, 3.333 and 
10 mg/plate 
Negative1 (Mortelmans et al., 
1986) 
 
(Methyl linoleate 
[09.646] & Methyl 
linolenate (mixture)  
Ames (His 
reversion) 
S. typhimurium TA100, 
TA98, TA102, TA97, 
TA1537 
1.0 mg/plate  Negative1 (MacGregor et al., 
1985) 
Tests were conducted with methyl 
linoleate and methyl linolenate 
separately, with the same result. 
(2,6-Dimethyl-5-heptenal 
[05.074]) 
Ames S. typhimurium TA1535, 
TA100, TA1537, 
TA1538, TA98 
3.6 mg/plate Negative1 (Wild et al., 1983)  
Ames S. typhimurium TA1535, 
TA100, TA1537, 
TA1538, TA98 
50 mg/plate Negative1 (Heck et al., 1989)  
(2,6-Dimethyl-5-heptenal 
[05.074]) 
UDS Rat hepatocytes 1.0 mg/ml Negative1 (Heck et al., 1989)  
Methyl methacrylate 
[09.647] 
Ames 
 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
As part of a bonecement 
extract 
Negative1 (Jensen et al., 1991)  
S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
150 - 4700 µg/plate Negative1 (Hachitani et al., 1982) The study cannot fully be evaluated 
as text is in Japanese, however, 
from the tables reported the result 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.05Rev2 (EFSA CEF Panel, 2010) 
Chemical Name  
[FL-no] 
Test System Test Object Concentration Result Reference Comments 
seems to be valid. 
S. typhimurium TA98, 
TA100, TA1535, TA1538 
100, 1000 and 9000 
ppm (tested as a gas) 
Negative1 (Anderson et al., 1979; 
Rohm & Haas Co., 
1976a) 
 
S. typhimurium TA97, 
TA98, TA100, TA1535, 
TA1537 
10 - 10000 µg/plate Negative1 (Zeiger, 1990)  
S. typhimurium TA98, 
TA100, TA1535, TA1538 
4 - 2500 µg/plate Negative1 (ICI, 1976a)  
S. typhimurium TA1535, 
TA1537, TA1538 
10 mg/plate Negative1 (DuPont, 1975)  
S. typhimurium TA98, 
TA100, TA1535, TA1537 
1000, 2500, 5000, 7500 
and 10000 µg/plate 
Negative1 (DuPont, 1979b)  
S. typhimurium TA100 10, 25 and 50 mM 
(liquid suspension 
assay) 
Weak positive1 (DuPont, 1979b) Cytotoxicity at all dose levels 
ranging from 21 - 58 % survival at 
low-dose level and 18 - 36 % 
survival at high-dose level. 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
1000 µg/plate Negative1 (Lijinsky & Andrews, 
1980) 
 
S. typhimurium TA97, 
TA98, TA100, TA1535 
33 - 10000 µg/plate Negative1 (NTP, 1986)  
S. typhimurium TA98, 
TA1535, TA1537, 
TA1538 
40 - 10000 µg/plate Negative1 (Waegemaekers and 
Bensink, 1984) 
 
S. typhimurium TA100 100 - 10000 µg/2 ml Negative1 (Waegemaekers and 
Bensink, 1984) 
 
S. typhimurium TA97a, 
TA98, TA100, TA102, 
TA104 
0.005 - 25 mg/plate 
(tested eluates in 
DMSO and saline; 100 
µl of eluate is expressed 
as 5 mg/plate) 
Negative (Schweikl et al., 1994)  
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.05Rev2 (EFSA CEF Panel, 2010) 
Chemical Name  
[FL-no] 
Test System Test Object Concentration Result Reference Comments 
S. typhimurium TA98, 
TA100, TA1537 
0.08 - 2.5 % Negative1 (DuPont, 1979a)  
S. typhimurium TA1535 0.08 - 2.5 % Negative2 
Weak positive3  
(DuPont, 1979a) Weak pos.: The dose levels selected 
for the test were nontoxic or only 
slightly toxic. 
S. typhimurium TA100 25 mM (suspension 
assay) 
Negative 2  
Weak positive3  
(DuPont, 1979a) Survival at 25 mM was 28 - 29 %. 
Forward mutation S. typhimurium TM677 10 - 100 mM Weak positive2  
Negative3  
(Poss et al., 1979) Relative survival was 0.50 at 10 
mM and 0.10 at 100 mM. 
S. typhimurium TM677 25 - 50 mM Weak positive2 (Haskell Laboratory, 
1989) 
Slight increase in mutagenicity, but 
percent survival was only 20 – 22 
% at low-dose level and 12 - 17 % 
at high-dose level. 
Chromosome 
aberrations 
CHO 5000 µg/ml (50 mM) Weak positive2 (Anderson et al., 1990) 
(NTP, 1986) 
Increase in percentage of aberrant 
cells was only at concentrations 
above 10 mM; no cytotoxicity data 
reported. 
CHO 1600 µg/ml (16 mM) Positive  (Anderson et al., 1990) 
(NTP, 1986) 
Increase in percentage of aberrant 
cells was only at concentrations 
above 10 mM; no cytotoxicity data 
reported. 
L5178Y TK+/- cells 2200 - 3000 µg/ml Weak positive3  (Doerr et al., 1989) Survival was 26 % at 2200 µg/ml 
and 12 % at 3000 µg/ml. 
Mouse lymphoma L5178Y TK+/- cells 500 µg/ml (5 mM) Positive2 (Amtower et al., 1986) No data on cytotoxicity available. 
L5178Y TK+/- cells 1000 - 3000 µg/ml (10 - 
30 mM) 
Positive3  (Moore et al., 1988) Mutagenic responses and increases 
of small colonies were small, not 
clearly dose-related and observed 
only at concentrations above 10 
mM. Dose-dependent effects on 
survival, with 60 % survival at 1000 
µg/ml; approximately 15 % survival 
at 3000 µg/ml. 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.05Rev2 (EFSA CEF Panel, 2010) 
Chemical Name  
[FL-no] 
Test System Test Object Concentration Result Reference Comments 
L5178Y TK+/- cells 2200 – 3000 µg/ml (22 
– 30 mM) 
Positive3  (Doerr et al., 1989) Increases of mutation frequencies 
occurred only at concentrations 
above 10 mM. There was a higher 
than normal level of small colonies 
in the control cultures. Dose-
dependent effects on survival, with 
53 % survival at 1000 µg/ml and 12 
% at 3000 µg/ml. 
L5178Y TK+/- cells 500 - 1000 µg/ml (5 – 
10 mM) 
Positive2 (Dearfield et al., 1991) Percent survival was approximately 
80 % at 500 µg/ml and 
approximately 40 % at 1000 µg/ml. 
L5178Y TK+/- cells 1500 - 3000 µg/ml (15 - 
30 mM) 
Positive3  (Dearfield et al., 1991) Percent survival was approximately 
50 % at 1500 µg/ml and 
approximately 15 % at 3000 µg/ml. 
L5178Y TK+/- cells 300 nl/ml  
(cytotoxic conc.) 100 
nl/ml  
Positive2  
Negative3  
(Rohm & Haas Co., 
1985) 
 
L5178Y TK+/- cells 0.125 - 1 µl/ml Positive2 
Ambiguous3  
(NTP, 1986) Ambiguous: Small but dose-related 
increases in mutant frequencies and 
numbers, but dose-related 
cytotoxicity was observed. 
L5178Y TK+/- cells  200 nl/ml  
500 - 1500 nl/ml  
Positive1 (Myhr et al., 1990) Treatments of 1500 nl/ml (without 
activation) and 2000 nl/ml (with 
activation) considered extremely 
toxic and/or lethal. No other 
cytotoxicity data available. 
SCE Human lymphocytes 0.1 µg/ml Negative3  (Cannas et al., 1987; 
Bigatti et al., 1989) 
 
CHO 16 - 5000 µg/ml Ambiguous1 (Anderson et al., 1990) Small increases in SCE frequency 
were reported. 
HRPT CH V79 B cells 10 - 20 µg/ml Very weak 
positive3  
(Schweikl et al., 1998) Survival was 71 % and 49 % at 10 
and 20 µg/ml, respectively. 
Cell transformation BHK21/C13 cells 0.01 - 0.000001 M Negative (Anderson et al., 1979)  
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.05Rev2 (EFSA CEF Panel, 2010) 
Chemical Name  
[FL-no] 
Test System Test Object Concentration Result Reference Comments 
Micronucleus Binucleated L5178Y cells 2200 - 3000 µg/ml (22 - 
30 mM) 
Ambiguous  (Doerr et al., 1989) Small but dose-related increases in 
mutant frequencies and numbers. 
Small but not clearly dose related 
increases in frequencies of micro-
nucleated cells. No cytotoxicity 
data reported. 
Ethyl methacrylate 
[09.375]  
Ames S. typhimurium TA98, 
TA100, TA1535, TA1537 
33 - 10000 µg/plate Negative1 (Zeiger et al., 1987)  
S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
40 - 2500 µg/plate Negative1 (Waegemaekers and 
Bensink, 1984) 
 
Mouse lymphoma L5178Y TK+/- cells > 1400 µg/ml Weak Positive3  (Moore et al., 1988) Negative at 1400 µg/ml and below; 
survival at 1400 µg/ml and above 
ranged from 2 % to 33 %, with 
cytotoxicity appearing to reach a 
plateau at concentrations above 
1500 µg/ml. 
SCE CHO NR Positive  (NTP, 1987) Abstract in table format only, study 
report not available for re-
evaluation. 
Isobutyl 2-methylprop-2-
enoate [09.586] 
Ames S. typhimurium TA98, 
TA100, TA1535, TA1537 
100, 333, 1000 and 
10000 µg/plate 
Negative1 (Zeiger et al., 1987)  
1 With and without metabolic activation. 
2 With metabolic activation. 
3 Without metabolic activation. 
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Table 4:  Genotoxicity Data (in vivo) for FGE.05Rev2 (EFSA CEF Panel, 2010) 
Chemical Name 
[FL-no] 
Test system Test Object Route Dose Result Reference Comments 
(2,6-Dimethyl-5-
heptenal 
[05.074]) 
  
Micronucleus  Mouse  
(bone marrow) 
IP injection  Single dose of 
0, 420, 980 and 
1540 mg/kg 
Negative (Wild et al., 1983) Limited quality since only a single 
sampling time (30 hours after treatment) 
was used and PCE/NCE ratio was not 
reported. Therefore it is not clear whether 
the substance had reached the bone 
marrow. 
Basc test (Sex-
linked recessive 
lethal mutation) 
D. melanogaster Diet 25 mM Negative (Wild et al., 1983) A single dose was tested in two 
experiments. Method not described in 
detail. 
Methyl methacrylate 
[09.647]  
Micronucleus Mouse  
(bone marrow) 
Gavage Single dose of 
1130 to 4520 
mg/kg or 4 
doses of 1130 
mg/kg 
Negative (Hachitani et al., 
1982) 
The study cannot be evaluated as text is 
in Japanese. Thus, e.g. it is not clear if 
samples were taken at different sampling 
times after single treatment and if 
sampling time was adequate after 
multiple treatment. Frequency of 
reticulocytes only slightly changed 
compared to control. Therefore it is not 
clear whether the substance had reached 
the bone marrow. 
Mouse 
(bone marrow) 
IP injection Single dose of 
methacrylate 
bone cement 
mixture 
Negative (Jensen et al., 
1991) 
Not relevant since an extract of a mixture 
(containing some additives used as 
accelerator, stabiliser, colourings etc.) 
was tested. 
Sex-linked recessive 
lethal mutation 
D. melanogaster Inhalation 1400 ppm Negative (Foureman et al., 
1994) 
Sufficient experimental details reported. 
Result is considered as valid. 
D. melanogaster Inhalation. 14000 ppm Negative (Foureman et al., 
1994) 
Sufficient experimental details reported. 
Result is considered as valid. 
Dominant lethal Mouse Inhalation, 6 
hours/day for 5 days 
100, 1000 and 
9000 ppm 
Negative (ICI, 1976b) Unpublished non-GLP study. Report 
contains sufficient details. Result is 
considered as valid. 
SCE Human (38 
male workers) 
Inhalation; 8 
hours/day 
0.9 - 71.9 ppm Negative (Seiji et al., 1994) Exposure period was not reported. 11 
unexposed subjects were used as controls. 
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Table 4:  Genotoxicity Data (in vivo) for FGE.05Rev2 (EFSA CEF Panel, 2010) 
Chemical Name 
[FL-no] 
Test system Test Object Route Dose Result Reference Comments 
A marginal increase was found (6.11 vs. 
4.91 SCEs/cell). However, this effect was 
considered to be age-related (and not 
dependent on methyl methacrylate 
exposure). Result is considered as valid. 
Chromosome 
aberrations  
Human  
(38 male 
workers) 
Inhalation; 8 
hours/day 
0.9 - 71.9 ppm Negative (Seiji et al., 1994) Exposure period was not reported. 11 
unexposed subjects were used as controls. 
Result is considered as valid. 
Rat  
(bone marrow) 
Inhalation, single 2 
hours exposure or 5 
hours/day for 5 days 
100 - 9000 ppm Weak 
positive  
(Rohm & Haas 
Co., 1976b; Rohm 
& Haas Co., 
1979) 
"Both studies suffer from inadequate 
description; esp. the second study 
demonstrates severe methodological 
problems, e.g., analysis of 50 metaphases 
was not possible for 10 out of 27 animals 
in the acute and 10 out 26 in the subacute 
test. Altogether, a clear conclusion cannot 
be drawn from these studies." (CEC 
2002). 
Isobutyl 2-methyl-prop-
2-enoate [09.586] 
Micronucleus Mouse Gavage 5000 mg/kg Negative (Roehm GmbH., 
1989) 
Reported to be in accordance with OECD 
Guideline 474, however, the study cannot 
be re-evaluated as only a summary of the 
EU-IUCLID database is available. 
According to this summary, a decrease of 
PCE/NCE ratio was observed. This 
indicates that the substance had reached 
the target cells. 
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Table 5:  Genotoxicity Data (in vitro) EFSA / FGE.202 (EFSA, 2009b) 
Chemical Name 
[FL-no]  
Test System Test Object  Concentration 
Reported 
Result  
Reference  Comments 
Citral 
[05.020] 
Reverse mutation 
 
S. typhimurium TA98, TA100, 
TA97a, TA102 
5 - 700 µg/plate Negativea (Gomes-Carneiro et 
al., 1998) 
Published non-GLP study containing 
sufficient details. Result is considered as 
valid. 
S. typhimurium TA92, TA94, 
TA98, TA100, TA1535, 
TA1537 
Up to 100 µg/plate Negativeb (Ishidate et al., 1984) Valid. According to current guidelines. The 
study is considered valid. 
S. typhimurium TA100 NR Negativea (Lutz et al., 1982) Validity cannot be evaluated. One strain only, 
Concentrations tested not specified. no re-run 
of the test; no other data on experimental 
results or design apart from a description of 
the test method. 
S. typhimurium TA98, TA100, 
TA1535, TA1537 
1 - 160 µg/plate Negativea (Zeiger et al., 1987)  
(NTP, 2003) 
Valid. Standard NTP study carried out 
according to US EPA Guidelines; result is 
considered valid. 
Mutation E. coli WP2uvrA (trp -) 13 - 100 µg/plate Negative (Yoo, 1986) Validity cannot be evaluated (study in 
Japanese). 
Sister chromatid 
exchange 
Chinese hamster ovary cells 0.289 - 40.2 µg/ml Positivea (NTP, 2003) Valid. Standard NTP study carried out 
according to US EPA Guidelines; result is 
considered valid. 
Chromosomal 
aberration 
Chinese hamster ovary cells 12.5 - 60.6 µg/ml Negativea (NTP, 2003) Valid. Standard NTP study carried out 
according to US EPA Guidelines; result is 
considered valid. 
Chinese hamster fibroblast cells Up to 30 µg/ml Negativec (Ishidate et al., 1984) Limited validity (performed only in the 
presence of metabolic activation). Study of 
limited validity. 
Rec assay B. subtilis M45 and H17 17 µg/disk Negative (Oda et al., 1979) The test system used is considered 
inappropriate; insufficient validity. 
B. subtilis M45 and H17 0.16, 0.32, 0.63 µl/disk 
(142, 284, 560 µg/disk)d 
1.25, 2.5 µl/disk  
(1110, 2220 µg/disk)d 
Negative 
 
Positive 
(Kuroda et al., 1984) Validity cannot be evaluated. Article in 
Japanese; with limited information in tables 
and abstract. Assay of limited relevance. 
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Table 5:  Genotoxicity Data (in vitro) EFSA / FGE.202 (EFSA, 2009b) 
Chemical Name 
[FL-no]  
Test System Test Object  Concentration 
Reported 
Result  
Reference  Comments 
Rec assay B. subtilis M45 and H17 < 2.5 µl/disk (< 2220 
µg/disk) 
Positive (Yoo, 1986) Validity cannot med evaluated (study in 
Japanese). Study of limited relevance. 
Induction of 
tumour suppressor 
protein p53 (DNA 
damage) 
Mouse fibroblast cells (NTCT 
929) 
10 - 30 µg/ml Positive (Duerksen-Hughes et 
al., 1999) 
The Induction of tumor suppressor protein 
p53 may be considered as indicator for 
genotoxicity. Result is considered valid, 
however, it has only limited relevance. 
3-methyl-2-
butenal 
[05.124] 
Ames test 
(preincubation) 
S. typhimurium TA98, TA100  Positivea (BASF, 1991) Valid. Modified Ames test: Unpublished non-
GLP study, carried out in accordance with the 
OECD Guideline 471. The study contains 
sufficient details and is considered valid. 
NR Not reported. 
a With and without metabolic activation. 
b With metabolic activation. 
c Without metabolic activation. 
d Calculated using a density of 0.888 (Merck Index, 1997). 
e Validity of genotoxicity studies: 
Valid. 
Limited validity (e.g. if certain aspects are not in accordance with OECD Guidelines or current standards and / or limited documentation). 
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate / not validated test system). 
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language). 
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Table 6:  Genotoxicity Data (in vivo) from FGE.202 (EFSA, 2009b) 
Chemical Name 
[FL-no]  
Test System Test Object  Route Dose Result  Reference  Comments a) 
Citral 
[05.020] 
Micronucleus 
formation 
Mouse bone marrow 
erythrocytes 
Three intraperitoneal 
injections given at 24-
hour intervals; male 
mice only 
250, 500, or 750 mg/kg bw Negative (NTP, 2003) NTP study carried out 
according to US-EPA 
Guideline. Result is 
considered as valid. 
Mouse peripheral blood 
erythrocytes 
Microencapsulated 
citral was 
administered in the 
diet for 14 weeks 
745, 1840, 3915, or 8110 
mg/kg bw per day (males) 
790, 1820, 3870, or 7550 
mg/kg bw per day (females) 
Negative 
 
Negative 
(NTP, 2003) NTP study carried out 
according to a non-standard 
guideline; result is considered 
of limited validity. 
3-methyl-2-butenal 
[05.124] 
UDS Rat hepatocytes Oral administration 350 and 700 mg/kg body 
weight 
Negative (BASF, 2001) Unpublished GLP study, 
carried out in accordance with 
OECD Guideline 486. The 
study is considered valid. 
Micronucleus 
test 
Mouse bone marrow 
erythrocytes 
Oral administration 175, 350 and 750 mg/kg 
body weight 
Negative (BASF, 1992) Unpublished GLP study, 
carried out in accordance with 
OECD Guideline (1991). The 
study is considered valid. 
Validity of genotoxicity studies: 
Valid. 
Limited validity (e.g. if certain aspects are not in accordance with OECD Guidelines or current standards and / or limited documentation). 
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate / not validated test system). 
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language). 
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Table 7:  Genotoxicity Data (in vitro) from FGE.207 (EFSA CEF Panel, 2013) 
Chemical Name 
[FL-no:] 
Test System 
in vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
2,6-Dimethyl-2,5,7-
octatriene-1-ol acetate 
[09.931] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 and TA102 
5 - 1500 μg/plate[1,3]; 
5 - 5000 μg/plate[2,3] 
 
Negative[1,3]; 
Equivocal[2,3] 
(King, 2000) Reliable without restriction. GLP study in 
compliance with OECD Guideline 471. A 
small increase in TA102 revertant numbers 
was seen at 15 and 50 μg/plate in the 
presence of S9-mix, but not at higher 
concentrations. 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 and TA102 
5 - 1500 μg/plate[1,3]; 
5 - 5000 μg/plate[2,3] 
 
Negative[1,3]; 
Negative[2,3] 
The small increase in TA102 revertant 
numbers seen in the first experiment at 15 
and 50 μg/plate in the presence of S9-mix 
was not reproduced in the second experiment. 
S. typhimurium TA102 5 - 1500 μg/plate[2,3] 
 
Negative The small increase in TA102 revertant 
numbers seen in the first experiment at 15 
and 50 μg/plate in the presence of S9-mix 
was not reproduced in the third experiment. 
Micronucleus 
Assay 
Human peripheral blood 
lymphocytes (Male 
Donors) 
70 - 120 μg/ml [1,4]; 
120 - 225 μg/mL 
[2,4]; 
20 - 60 μg/mL [1,5]; 
119.2 - 290 μg/mL 
[2,4] 
Weak positive +S9; 
Re-test within 
normal values 
(Whitwell, 2012) Reliable without restriction. GLP study in 
compliance with OECD Guideline 487. Weak 
evidence of inducing micronuclei in the 
presence of S9-mix in a first experiment 
(increases only in one culture). A re-test 
under the same conditions and using a higher 
top concentration resulted in MNBN 
frequencies within the historical negative 
control range at 95th percentile, but were 
statistically significant due to low vehicle 
control values.  
[1] Without S9-mix metabolic activation. 
[2] With S9-mix metabolic activation. 
[3] Plate incorporation method. 
[4] 3-hour incubation with 21-hour recovery period. 
[5] 24-hour incubation with no recovery period. 
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SUMMARY OF SAFETY EVALUATIONS 
Table 8:  Summary of Safety Evaluation by the JECFA (JECFA, 2004b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
( g/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on 
the named 
compound [4) 
or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion 
on the material of 
commerce 
02.011 
1219 
Citronellol 
 
320 
0.5 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
02.012 
1223 
Geraniol  
 
550 
315 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.202, 
genotoxicity concern 
could be ruled out. No 
safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
02.027 
1222 
Rhodinol  
 
13 
8.4 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
02.029 
1230 
3,7,11-
Trimethyldodeca-
2,6,10-trien-1-ol 
 
 
7.7 
2.6 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
02.058 
1224 
Nerol 
 
250 
171 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
02.076 
1199 
2-Methylbutan-1-ol 
 
0.73 
35 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
02.109 
1200 
3-Methylbut-2-en-1-ol 
 
4.6 
3.8 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
No safety concern at 
the estimated level 
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Table 8:  Summary of Safety Evaluation by the JECFA (JECFA, 2004b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
( g/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on 
the named 
compound [4) 
or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion 
on the material of 
commerce 
based on the MSDI 
approach. 
of intake based on 
the MSDI approach. 
05.021 
1220 
Citronellal 
 
810 
324 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
05.124 
1202 
3-
Methylcrotonaldehyde 
 
3.3 
0.5 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
05.148 
1228 
Farnesal 
 
0.49 
0.2 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
05.169 
1229 
12-Methyltridecanal  
 
0.24 
0.5 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
08.036 
1221 
Citronellic acid 
 
2.7 
0.2 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
08.044 
1211 
2,4-Dimethylpent-2-
enoic acid 
 
0.12 
0.1 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
08.047 
1212 
2-Methylheptanoic acid 
 
14 
6 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
08.055 
1210 
2-Methyl-2-pentenoic 
acid 
 
36 
20 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
No safety concern at 
the estimated level 
of intake based on 
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Table 8:  Summary of Safety Evaluation by the JECFA (JECFA, 2004b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
( g/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on 
the named 
compound [4) 
or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion 
on the material of 
commerce 
approach. the MSDI approach. 
08.064 
1205 
2-Methylcrotonic acid 
 
4.1 
1.6 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
08.070 
1204 
3-Methylcrotonic acid 
 
0.012 
0.01 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
08.079 
1218 
4-Ethyloctanoic acid 
 
0.73 
4 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
09.273 
1206 
Isobutyl crotonate 
 
0.46 
45 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
09.408 
1213 
Isobutyl 2-methylbut-
2(cis)-enoate 
 
0.12 
0.1 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
09.931 
1226 
2,6-Dimethyl-2,5,7-
octatriene-1-ol acetate 
 
1.2 
7.7 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.001 
1203 
Ammonium isovalerate 
 
15 
16 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
05.020 
1225 
Citral 
 
5844 
6990 
Class I 
A3: Intake above threshold 
A4: Not endogenous 
A5: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
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1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND not determined 
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.05Rev2) (EFSA CEF Panel, 2010) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
08.072 
 
But-2-enoic acid (cis and 
trans) 
 
4.0 
 
Class I 
A3: Intake below threshold 
4) 7)  
08.083 
 
Hept-2-enoic acid 
 
6.1 
 
Class I 
A3: Intake below threshold 
4) 7)  
08.101 
 
Non-2-enoic acid 
 
6.1 
 
Class I 
A3: Intake below threshold 
4) 7)  
08.119 
 
2-Hexenoic acid 
 
240 
 
Class I 
A3: Intake below threshold 
4) 7)  
08.120 
 
2-Methyl-2-butenoic acid 
 
6.1 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.181 
 
Methyl hex-2-enoate 
 
0.037 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.248 
 
Ethyl trans-2-butenoate 
 
12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.266 
1807 
Hexyl 2-butenoate 
 
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.321 
 
Butyl 2-methylbut-2(cis)-
enoate 
 
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.05Rev2) (EFSA CEF Panel, 2010) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
09.324 
 
Butyl but-2-enoate 
 
1.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.326 
 
Butyl deca-2,4-dienoate 
 
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.329 
 
Butyl hex-2-enoate 
 
1.0 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.330 
 
Butyl hex-3-enoate 
 
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.335 
 
Butyl oct-2-enoate 
 
0.66 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.365 
 
Ethyl 3-methylcrotonate 
 
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.370 
 
Ethyl dec-9-enoate 
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.372 
 
Ethyl dodec-2-enoate 
 
0.34 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.374 
 
Ethyl hept-2-enoate 
 
0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.05Rev2) (EFSA CEF Panel, 2010) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
09.379 
 
Ethyl pent-2-enoate 
 
0.037 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.596 
 
Isopentyl 2-
methylcrotonate 
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.603 
 
Isopropyl crotonate 
 
0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.624 
 
Methyl 2-methylcrotonate 
 
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.625 
 
Methyl 2-methylpent-3-
enoate 
 
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.636 
 
Methyl crotonate 
 
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.637 
 
Methyl dec-2-enoate 
 
0.37 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.641 
 
Methyl dodec-2-enoate 
 
0.56 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.652 
 
Methyl oleate 
 
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.680 
 
Pentyl 2-
methylisocrotonate 
 
0.74 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.05Rev2) (EFSA CEF Panel, 2010) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
09.699 
 
Propyl crotonate 
O
O
 
0.085 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.865 
 
Hexyl 9-octadecenoate 
 
0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.934 
1630 
Methyl (5Z)-Octenoate 
 
3.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.942 
 
2-Methylbutyl-3-methyl-
2-butenoate 
 
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.287 
 
Propyl deca-2,4-dienoate 
 
0.61 
 
Class I 
A3: Intake below threshold 
4) 8)  
09.578 
 
Hexyl crotonate 
 
2.6 
 
Class I 
A3: Intake below threshold 
4) 8)  
09.375 
 
Ethyl methacrylate 
 
0.12 
 
Class II 
A3: Intake below threshold 
4) 6)  
09.586 
 
Isobutyl 2-methylprop-2-
enoate 
 
0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
09.647 
1834 
Methyl methacrylate 
 
0.061 
 
Class II 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
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5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at the estimated level of intake of the material of commerce meeting the specification requirements (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on 
stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFFA  European Flavour and Fragrance Association 
EFSA  European Food Safety Authority 
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
HPRT  Hypoxanthine Phosphoribosyl transferase 
ID  Identity 
IP  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MNBN  Micronucleated Binucleate cells 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organization for Economic Co-operation and Development 
PCE  Polychromatic erythrocyte 
RI  Replication Index 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
UDS  Unscheduled DNA Synthesis 
WHO  World Health Organization 
